Kolaborasi Fortrea dan Omico untuk Mendorong Pengembangan Obat Onkologi Berbasis Biomarker

Fortrea, a leading global contract research organization, has partnered with Omico, Australia's precision oncology leader, to accelerate biomarker-driven cancer research. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve clinical trial site selection, patient recruitment, and access to biomarker-matched trials in Australia, leveraging Omico's database of over 23,000 consented patients and 1,600+ referring physicians.